Prevention of Pegfilgrastim-Induced Bone Pain (PIBP)

ClinicalTrials.gov ID: NCT00602420

Public ClinicalTrials.gov record NCT00602420. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 28, 2026, 9:19 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Prevention of Pegfilgrastim-Induced Bone Pain (PIBP): A Phase III Double-Blind Placebo-Controlled Clinical Trial

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

RATIONALE: Naproxen may help prevent or lessen bone pain caused by pegfilgrastim. It is not yet known whether naproxen is more effective than a placebo in preventing bone pain caused by pegfilgrastim in patients with non-hematologic cancer undergoing chemotherapy. PURPOSE: This randomized phase III trial is studying naproxen to see how well it works compared with a placebo in preventing bone pain caused by pegfilgrastim in patients with non-hematologic cancer undergoing chemotherapy.

Study identification

NCT ID: NCT00602420
Recruitment status: Completed
Study type: Interventional
Phase: Phase 3
Lead sponsor: Gary Morrow; Other
Enrollment: 510 participants

Conditions and interventions

Conditions

Interventions

naproxen Drug
placebo Other

Drug · Other

Eligibility (public fields only)

Age range: 18 Years to 120 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jun 2008 (Type not available)
Primary completion: Jan 2012 (Actual)
Completion: Mar 2012 (Actual)
Last update posted: Nov 9, 2015

2008 – 2012

United States locations

U.S. sites: 16
U.S. states: 12
U.S. cities: 16

Facility	City	State	ZIP	Site status
MBCCOP - Hawaii	Honolulu	Hawaii	96813	—
CCOP - Central Illinois	Decatur	Illinois	62526	—
CCOP - Evanston	Evanston	Illinois	60201	—
CCOP - Wichita	Wichita	Kansas	67214-3882	—
CCOP - Grand Rapids	Grand Rapids	Michigan	49503	—
CCOP - Metro-Minnesota	Saint Louis Park	Minnesota	55416	—
CCOP - Kansas City	Kansas City	Missouri	64131	—
CCOP - Hematology-Oncology Associates of Central New York	Syracuse	New York	13215	—
CCOP - Southeast Cancer Control Consortium	Goldsboro	North Carolina	27534-9479	—
CCOP - Columbus	Columbus	Ohio	43215	—
CCOP - Dayton	Dayton	Ohio	45429	—
CCOP - Greenville	Greenville	South Carolina	29615	—
CCOP - Upstate Carolina	Spartanburg	South Carolina	29303	—
CCOP - Virginia Mason Research Center	Seattle	Washington	98101	—
CCOP - Northwest	Tacoma	Washington	98405-0986	—
CCOP - Marshfield Clinic Research Foundation	Marshfield	Wisconsin	54449	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00602420, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Nov 9, 2015 · Synced Oct 28, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00602420 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →